Imidazo[4,5-C]pyridine derived SSAO inhibitors

1. A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:

wherein Y is selected from hydrogen, hydroxyl, —NH 2 , —NH—C 1-4 -alkyl, —NH-halo-C 1-4 -alkyl, or —C 1-4 -alkoxy;

wherein Z is selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, —CONH 2 , —SO 2 NH 2 , —NH 2 , —NHC 1-4 -alkyl, and —NH-halo-C 1-4 -alkyl;

wherein R 1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring optionally substituted with one or more substituents selected from halogen, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, —OR 5 , NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , and —NR 6 S(O) 2 R 5 ;

wherein R 4A , R 4B , R 5 , and R 6 are each independently selected from hydrogen, C 1-4 -alkyl and halo-C 1-4 -alkyl, or

wherein each of R 4A and R 4B , together with the nitrogen to which they are attached, form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, —CONH 2 , —SO 2 NH 2 , —NH 2 , —NHC 1-4 -alkyl, and —NH-halo-C 1-4 -alkyl;

wherein W is a [6,5] heteroaryl ring system formed by fusing together phenyl and pyrrolidinyl or imidazolyl and wherein either ring is optionally substituted with one or more groups selected from halogen, oxo, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, —OR 5 , —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , —SO 2 NR 4A R 4B , and —NR 6 S(O) 2 R 5 ;

wherein V is a direct bond; and

wherein R 3 is hydrogen.

2. The compound according to claim 1 , wherein W has the formula A1 or A2:

3. A method for the treatment of inflammation, which comprises administering to a subject suffering such disease an effective amount of a compound according to claim 1 .

4. A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:

wherein Y is selected from hydrogen, hydroxyl, —NH 2 , —NH—C 1-4 -alkyl, —NH-halo-C 1-4 -alkyl, and —C 1-4 -alkoxy;

wherein Z is selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, —CONH 2 , —SO 2 NH 2 , —NH 2 , —NHC 1-4 -alkyl, and —NH-halo-C 1-4 -alkyl;

wherein R 1 is a phenyl ring, or a 5 or 6-membered heteroaryl ring, either ring optionally substituted with one or more substituents selected from halogen, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, —OR 5 , —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , and —NR 6 S(O) 2 R 5 ;

wherein R 4A , R 4B , R 5 , and R 6 are each independently selected from hydrogen, C 1-4 -alkyl and halo-C 1-4 -alkyl, or

wherein each of R 4A and R 4B , together with the nitrogen to which they are attached, form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from: halogen, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, halo-C 1-4 -alkoxy, —CONH 2 , —SO 2 NH 2 , —NH 2 , —NHC 1-4 -alkyl, and —NH-halo-C 1-4 -alkyl;

wherein W is a 5 or 6-membered heterocyclic ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, —OR 5 , —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , —SO 2 NR 4A R 4B , and —NR 6 S(O) 2 R 5 ;

wherein V is a direct bond; and

wherein R 3 is a phenyl ring or a 5 or 6-membered heteroaryl ring optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, —OR 5 , —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , —SO 2 NR 4A R 4B and —NR 6 S(O) 2 R 5 .

5. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , and a pharmaceutically acceptable carrier.

6. A method for the treatment of inflammation, which comprises administering to a subject suffering such disease an effective amount of a compound according to claim 4 .

7. A pharmaceutical composition comprising an effective amount of a compound according to claim 4 , and a pharmaceutically acceptable carrier.

8. The compound according to claim 1 , wherein the compound is:

9. The method according to claim 3 , wherein the compound is:

10. The compound according to claim 4 , wherein the compound is:

11. The method according to claim 6 , wherein the compound is:

12. The compound according to claim 4 , wherein W is a ring selected from piperidine, morpholine, pyrrolidine, and piperazine, any of which is optionally substituted with one or more groups selected from halogen, oxo, hydroxyl, cyano, C 1-4 -alkyl, halo-C 1-4 -alkyl, cyano-C 1-4 -alkyl, —OR 5 , —NR 4A R 4B , —NR 6 C(O)OR 5 , —NR 6 C(O)R 5 , —NR 6 C(O)NR 4A R 4B , —C(O)NR 4A R 4B , —C(O)R 5 , —C(O)OR 5 , —SO 2 R 5 , —SO 2 NR 4A R 4B , and —NR 6 S(O) 2 R 5 .

13. The compound according to claim 12 , wherein —WVR 3 is:

14. The compound according to claim 4 , wherein R 3 is selected from phenyl, pyridyl, and pyrimidinyl, any of which is optionally substituted with oxo.

15. The compound according to claim 12 , wherein R 3 is selected from phenyl, pyridyl and pyrimidinyl, any of which is optionally substituted with oxo.

16. The compound according to claim 13 , wherein R 3 is selected from phenyl, pyridyl and pyrimidinyl, any of which is optionally substituted with oxo.